Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women with a Pelvic Mass

Overview

Journal Obstet Gynecol

Specialty Gynecology & Obstetrics

Date 2011 Jul 22

PMID 21775843

Citations 104

Authors

Richard G Moore

M Craig Miller

Paul DiSilvestro

Lisa M Landrum

Walter Gajewski

John J Ball

Steven J Skates

Affiliations

Soon will be listed here.

Abstract

Objective: It is often difficult to distinguish a benign pelvic mass from a malignancy and tools to help referring physician are needed. The purpose of this study was to validate the Risk of Ovarian Malignancy Algorithm in women presenting with a pelvic mass.

Methods: This was a prospective, multicenter, blinded clinical trial that included women who presented to a gynecologist, a family practitioner, an internist, or a general surgeon with an adnexal mass. Serum HE4 and CA 125 were determined preoperatively. A Risk of Ovarian Malignancy Algorithm score was calculated and classified patients into high-risk and low-risk groups for having a malignancy. The sensitivity, specificity, negative predictive value, and positive predictive value of the Risk of Ovarian Malignancy Algorithm were estimated.

Results: A total of 472 patients were evaluated with 383 women diagnosed with benign disease and 89 women with a malignancy. The incidence of all cancers was 15% and 10% for ovarian cancer. In the postmenopausal group, a sensitivity of 92.3% and a specificity of 76.0% and for the premenopausal group the Risk of Ovarian Malignancy Algorithm had a sensitivity of 100% and specificity of 74.2% for detecting ovarian cancer. When considering all women together, the Risk of Ovarian Malignancy Algorithm had a sensitivity of 93.8%, a specificity of 74.9%, and a negative predictive value of 99.0%.

Conclusion: The use of the serum biomarkers HE4 and CA 125 with the Risk of Ovarian Malignancy Algorithm has a high sensitivity for the prediction of ovarian cancer in women with a pelvic mass. These findings support the use of the Risk of Ovarian Malignancy Algorithm as a tool for the triage of women with an adnexal mass to gynecologic oncologists.

Level Of Evidence: II.

Citing Articles

Metabolomics of Papanicolaou Tests for the Discovery of Ovarian Cancer Biomarkers.

Sah S, Schwiebert E, Moore S, Liu Y, Gaul D, Boylan K Metabolites. 2024; 14(11).

PMID: 39590836 PMC: 11596055. DOI: 10.3390/metabo14110600.

Machine-learning diagnostic models for ovarian tumors.

Sun Y, Wen B Heliyon. 2024; 10(19):e36994.

PMID: 39381112 PMC: 11456824. DOI: 10.1016/j.heliyon.2024.e36994.

Investigating harms of testing for ovarian cancer - psychological outcomes and cancer conversion rates in women with symptoms of ovarian cancer: A cohort study embedded in the multicentre ROCkeTS prospective diagnostic study.

Kwong F, Kristunas C, Davenport C, Aggarwal R, Deeks J, Mallett S BJOG. 2024; 131(10):1400-1410.

PMID: 38556698 PMC: 7616335. DOI: 10.1111/1471-0528.17813.

Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.

Ghose A, McCann L, Makker S, Mukherjee U, Gullapalli S, Erekkath J Ther Adv Med Oncol. 2024; 16:17588359241233225.

PMID: 38435431 PMC: 10908239. DOI: 10.1177/17588359241233225.

Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women.

Sah S, Bifarin O, Moore S, Gaul D, Chung H, Kwon S Cancer Epidemiol Biomarkers Prev. 2024; 33(5):681-693.

PMID: 38412029 PMC: 11061607. DOI: 10.1158/1055-9965.EPI-23-1293.

References

. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002; 100(6):1413-6. DOI: 10.1016/s0029-7844(02)02630-3. View

Drapkin R, von Horsten H, Lin Y, C Mok S, Crum C, Welch W . Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6):2162-9. DOI: 10.1158/0008-5472.CAN-04-3924. View

Engelen M, Kos H, Willemse P, Aalders J, de Vries E, Schaapveld M . Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2005; 106(3):589-98. DOI: 10.1002/cncr.21616. View

Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter J, Schummer M, McIntosh M . The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63(13):3695-700. View

Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast Jr R . Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010; 117(3):440-5. PMC: 2873171. DOI: 10.1016/j.ygyno.2010.02.005. View

Moore R, Brown A, Miller M, Skates S, Allard W, Verch T . The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2007; 108(2):402-8. DOI: 10.1016/j.ygyno.2007.10.017. View

Giede K, Kieser K, Dodge J, Rosen B . Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol. 2005; 99(2):447-61. DOI: 10.1016/j.ygyno.2005.07.008. View

Moore R, Brown A, Miller M, Badgwell D, Lu Z, Allard W . Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008; 110(2):196-201. PMC: 3594093. DOI: 10.1016/j.ygyno.2008.04.002. View

Hough C, Pizer E, Montz F, Im D, Rosenshein N, Cho K . Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000; 60(22):6281-7. View

10.

Kim Y, Whang D, Park J, Kim S, Lee S, Park H . Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med. 2011; 49(3):527-34. DOI: 10.1515/CCLM.2011.085. View

11.

Woolas R, Xu F, Jacobs I, Yu Y, Daly L, Berchuck A . Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993; 85(21):1748-51. DOI: 10.1093/jnci/85.21.1748. View

12.

Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H . Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009; 100(8):1315-9. PMC: 2676558. DOI: 10.1038/sj.bjc.6605011. View

13.

Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M . The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin Chem Lab Med. 2011; 49(3):521-5. DOI: 10.1515/CCLM.2011.075. View

14.

Goff B, Matthews B, Larson E, Andrilla C, Wynn M, Lishner D . Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer. 2007; 109(10):2031-42. DOI: 10.1002/cncr.22604. View

15.

Mercado C, Zingmond D, Karlan B, Sekaris E, Gross J, Maggard-Gibbons M . Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol. 2010; 117(1):18-22. DOI: 10.1016/j.ygyno.2009.12.033. View

16.

. Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol Oncol. 2000; 78(3 Pt 2):S1-13. DOI: 10.1006/gyno.2000.5887. View

17.

Bristow R, Palis B, Chi D, Cliby W . The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010; 118(3):262-7. DOI: 10.1016/j.ygyno.2010.05.025. View

18.

Bast Jr R, Klug T, St John E, Jenison E, Niloff J, Lazarus H . A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309(15):883-7. DOI: 10.1056/NEJM198310133091503. View

19.

Galgano M, Hampton G, Frierson Jr H . Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19(6):847-53. DOI: 10.1038/modpathol.3800612. View

20.

Moore R, Jabre-Raughley M, Brown A, Robison K, Miller M, Allard W . Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010; 203(3):228.e1-6. PMC: 3594101. DOI: 10.1016/j.ajog.2010.03.043. View